title: PET imaging of tumour hypoxia.
abstract: Tumour hypoxia represents a significant challenge to the curability of human tumours leading to treatment resistance and enhanced tumour progression. Tumour hypoxia can be detected by non-invasive and invasive techniques but the inter-relationships between these remains largely undefined. [18F]Fluoromisonidazole-3-fluoro-1-(2'-nitro-1'-imidazolyl)-2-propanol ([18F]MISO) and Cu-diacetyl-bis(N4-methylthiosemicarbazone (Cu-ATSM)-positron emission tomography (PET), and blood oxygen level-dependent (BOLD)-magnetic resonance imaging (MRI) are the lead contenders for human application based on their non-invasive nature, ease of use and robustness, measurement of hypoxia status, validity, ability to demonstrate heterogeneity and general availability; PET techniques are the primary focus of this review.
authors.affiliation: Paul Strickland Scanner Centre, Mount Vernon Hospital, Rickmansworth Road, Northwood, Middlesex, HA6 2RN, UK. anwar.padhani@paulstrickland-scannercentre.org.uk
authors.forename: Anwar
authors.initials: A
authors.lastname: Padhani
mesh_terms: D015687:Cell Hypoxia; D056831:Coordination Complexes; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods; D008920:Misonidazole / Q000031:analogs & derivatives / Q000493:pharmacokinetics; D009369:Neoplasms / Q000098:blood supply / Q000000981:diagnostic imaging* / Q000378:metabolism / Q000473:pathology; D009942:Organometallic Compounds / Q000493:pharmacokinetics; D010100:Oxygen / Q000097:blood; D049268:Positron-Emission Tomography / Q000379:methods; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D013882:Thiosemicarbazones / Q000493:pharmacokinetics
chemical_list: D056831:Coordination Complexes; D009942:Organometallic Compounds; D019275:Radiopharmaceuticals; D013882:Thiosemicarbazones; C089548:copper (II) diacetyl-di(N(4)-methylthiosemicarbazone); C031843:fluoromisonidazole; D008920:Misonidazole; D010100:Oxygen